Trial Profile
Placebo-Controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of CHF5074 in Healthy Young Male Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 13 Feb 2015
Price :
$35
*
At a glance
- Drugs Itanapraced (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Chiesi
- 20 Jul 2011 Results presented at the 2011 International Conference on Alzheimer's Disease.
- 23 Feb 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 07 Oct 2010 New trial record